Progress and prospects: stem cells and neurological diseases

Gögel, Stefanie; Gubernator, Miriam; Minger, Stephen

doi:10.1038/gt.2010.130

Cited by 105 publications

(83 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The NSC have neuronal specific markers called nestin, MAP-2, and tyrosine hydroxylase (TH) [51]. The prolonged culturing of the NSC lead to an ever increasing glial differentiation pattern at the expense of neuronal differentiation, which significantly reduces the therapeutic potential of the NSC [6]. Furthermore, neural progenitor cells (NPC) and oligodendrocyte progenitor cells (OPC) are embedded in the adult CNS requiring invasive techniques to acquire [2,52].…”

Section: Allogeneic Umbilical Cord Msc (Ucmsc)mentioning

confidence: 99%

See 1 more Smart Citation

The Use of Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis: An Overview of Open Labels and Ongoing Studies

Shahbeigi¹,

Ali²,

Joel³

2014

J Neurol Neurophysiol

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a demyelinating disease of unknown etiology that affects the Central Nervous System (CNS) where autoimmune-mediated mechanisms are thought to be at work. There are two possible options for treating MS, to prevent damage, and to repair the already impaired CNS. Stem Cells (SC) therapy emerges as a potential new hope for MS patients as it could accomplish both functions. There is a growing body of literature that supports the potential of the SC for immunomodulation and re-myelination. Here we focus on examining the registered published and on-going clinical trials using the Mesenchymal Stem Cell (MSC) therapy in MS. We have found that a total of 85 patients were enrolled in 9 cell-base studies with encouraging results. These studies were not statistically analyzed; however, they showed safety of the MSC therapy. Based on the results emerging from these patients, who failed to respond to even immunosuppressive drugs, clinical improvement was observed in 62%, a stable course in 22%; and 16% remaining in a progressive course. Given the evidence, we support that cell-based therapies are safe and reasonable to initiate a double blind, randomized controlled trials. This would represent a new and unique therapeutic approach for the progressive forms of MS.

show abstract

Section: Allogeneic Umbilical Cord Msc (Ucmsc)mentioning

confidence: 99%

“…Blastocysts are the first stage of developmental differentiation of embryonic cells, with an outer trophoblastic layer and an inner cell mass [5,6]. The Embryonic stem cells (ESC) are derived from the inner cell mass and are pluripotent cells capable of differentiating into three primary germ layers [7].…”

Section: Introductionmentioning

confidence: 99%

The Use of Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis: An Overview of Open Labels and Ongoing Studies

Shahbeigi¹,

Ali²,

Joel³

2014

J Neurol Neurophysiol

View full text Add to dashboard Cite

show abstract

“…The first strategy is through donor cell transplantation (from either autologous or allogenic cell sources). Over the last decade, credible data have demonstrated the safety and feasibility of injected stem cells in inducing neural cell regeneration and functional recovery in animal models of stroke, Parkinson's disease, Huntington's disease, and Alzheimer's disease (Gogel et al 2011;Francis and Wei 2010;Haider and Ashraf 2010;Herrmann et al 2010;Savitz et al 2011). Human neural stem cells (HNSCs) transplanted into aged rat brains differentiated into neural cells and significantly improved the cognitive functions of the animals (Sugaya 2005;Sugaya et al 2006;Roitberg et al 2006;Qu et al 2001;Winkler 2001).…”

Section: Stem Cell Therapy Of Neurodegenerative Diseases and Strokementioning

confidence: 99%

“…Human neural stem cells (HNSCs) transplanted into aged rat brains differentiated into neural cells and significantly improved the cognitive functions of the animals (Sugaya 2005;Sugaya et al 2006;Roitberg et al 2006;Qu et al 2001;Winkler 2001). Cells from different sources have been examined and proved effective, including neural stem cells (NSC) derived from embryonic stem (ES) cells or induced pluripotent stem (iPS) cells, and fetal or adult neural stem cells (Zeng et al 2010;Gogel et al 2011;Haider and Ashraf 2010;Wang et al 2011;Haas et al 2005;Wang et al 2009;Theus et al 2008;Wei et al 2012;Kelly et al 2004;Bliss et al 2006;Horie et al 2011). Pluripotent stem cells are no longer seen as a safe cell sources as its transplantation leads to teratoma formation (Gogel et al 2011).…”

Section: Stem Cell Therapy Of Neurodegenerative Diseases and Strokementioning

confidence: 99%

“…It could aid in easing symptoms or even reverse disease progression of diseases where pharmacological interventions and other treatment modalities are no longer sufficient or not available (Gogel et al 2011). This is especially true for diseases associated with aging such as neurodegenerative diseases, type II diabetes, and heart failure (Haas et al 2005;Chang et al 2007;Caspi et al 2007).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hormesis, Cell Death, and Regenerative Medicine for Neurodegenerative Diseases

Wang¹

2012

Dose-Response

View full text Add to dashboard Cite

ᮀ Although the adult human brain has a small number of neural stem cells, they are insufficient to repair the damaged brain to achieve significant functional recovery for neurodegenerative diseases and stroke. Stem cell therapy, by either enhancing endogenous neurogenesis, or transplanting stem cells, has been regarded as a promising solution. However, the harsh environment of the diseased brain posts a severe threat to the survival and correct differentiation of those new stem cells. Hormesis (or preconditioning, stress adaptation) is an adaptation mechanism by which cells or organisms are potentiated to survive an otherwise lethal condition, such as the harsh oxidative stress in the stroke brain. Stem cells treated by low levels of chemical, physical, or pharmacological stimuli have been shown to survive better in the neurodegenerative brain. Thus combining hormesis and stem cell therapy might improve the outcome for treatment of these diseases. In addition, since the cell death patterns and their underlying molecular mechanism may vary in different neurodegenerative diseases, even in different progression stages of the same disease, it is essential to design a suitable and optimum hormetic strategy that is tailored to the individual patient.

show abstract